

Occurred: Ch. 683, Acts of 1999. Correction by the publisher of the Annotated Code in the 1999 Supplement of the Insurance Article is validated by this Act.

15-827.

(e) The coverage under subsection (d) of this section shall be required if:

(1) (i) the treatment is being provided or the studies are being conducted in a Phase I, Phase II, Phase III, or Phase IV clinical trial for cancer; or

(ii) the treatment is being provided in a Phase I, Phase II, Phase III, or Phase IV clinical trial for any other life-threatening condition;

(2) the treatment is being provided in a clinical trial approved by:

(i) one of the National Institutes of Health;

(ii) an NIH cooperative group or an NIH center;

(iii) the FDA in the form of an investigational new drug application;

(iv) the federal Department of Veterans Affairs; or

(v) an institutional review board of an institution in the state which has a multiple project assurance contract approved by the Office of Protection from Research Risks of the National Institutes of Health;

(3) the facility and personnel providing the treatment are capable of doing so by virtue of their experience, training, and volume of patients treated to maintain expertise;

(4) there is no clearly superior, noninvestigational treatment alternative; and

(5) the available clinical or preclinical data provide a reasonable expectation that the treatment will be at least as effective as the noninvestigational alternative.

DRAFTER'S NOTE:

Error: Incorrect word usage in § 15-827(e)(2)(v) of the Insurance Article.

Occurred: Chs. 145 and 146, Acts of 1999. Correction by the publisher of the Annotated Code in the 1999 Supplement of the Insurance Article is validated by this Act.

17-201.

(b) (1) The employees eligible for insurance under the policy shall be all of the employees of the employer, or all [or] OF any class or classes of employees.

DRAFTER'S NOTE:

Error: Incorrect word usage in § 17-201(b)(1) of the Insurance Article.